The purpose of this legislation is to improve healthcare coverage for individuals suffering from Alpha-1 Antitrypsin Deficiency Disorder, a genetic condition that can lead to serious lung and liver problems. The law aims to ensure that treatments for this disorder are covered under Medicare, specifically under Part B, which deals with outpatient care. Key provisions of the legislation include the establishment of coverage for Alpha-1 Antitrypsin Deficiency Disorder treatment, which is defined as augmentation therapy.